These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
273 related articles for article (PubMed ID: 21805352)
21. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin. Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658 [TBL] [Abstract][Full Text] [Related]
22. Arylamino Esters As P-Glycoprotein Modulators: SAR Studies to Establish Requirements for Potency and Selectivity. Teodori E; Dei S; Floriddia E; Perrone MG; Manetti D; Romanelli MN; Contino M; Colabufo NA ChemMedChem; 2015 Aug; 10(8):1339-43. PubMed ID: 26012726 [TBL] [Abstract][Full Text] [Related]
23. Bifendate-chalcone hybrids: a new class of potential dual inhibitors of P-glycoprotein and breast cancer resistance protein. Gu X; Ren Z; Peng H; Peng S; Zhang Y Biochem Biophys Res Commun; 2014 Dec; 455(3-4):318-22. PubMed ID: 25446092 [TBL] [Abstract][Full Text] [Related]
24. Computational classification models for predicting the interaction of drugs with P-glycoprotein and breast cancer resistance protein. Erić S; Kalinić M; Ilić K; Zloh M SAR QSAR Environ Res; 2014; 25(12):939-66. PubMed ID: 25435255 [TBL] [Abstract][Full Text] [Related]
25. Interaction profile of macitentan, a new non-selective endothelin-1 receptor antagonist, in vitro. Weiss J; Theile D; Rüppell MA; Speck T; Spalwisz A; Haefeli WE Eur J Pharmacol; 2013 Feb; 701(1-3):168-75. PubMed ID: 23353592 [TBL] [Abstract][Full Text] [Related]
26. Parguerenes: Marine red alga bromoditerpenes as inhibitors of P-glycoprotein (ABCB1) in multidrug resistant human cancer cells. Huang XC; Sun YL; Salim AA; Chen ZS; Capon RJ Biochem Pharmacol; 2013 May; 85(9):1257-68. PubMed ID: 23415901 [TBL] [Abstract][Full Text] [Related]
27. Interaction Studies of Resolvin E1 Analog (RX-10045) with Efflux Transporters. Cholkar K; Trinh HM; Vadlapudi AD; Wang Z; Pal D; Mitra AK J Ocul Pharmacol Ther; 2015 May; 31(4):248-55. PubMed ID: 25844889 [TBL] [Abstract][Full Text] [Related]
28. Ingredients in fruit juices interact with dasatinib through inhibition of BCRP: a new mechanism of beverage-drug interaction. Fleisher B; Unum J; Shao J; An G J Pharm Sci; 2015 Jan; 104(1):266-75. PubMed ID: 25418056 [TBL] [Abstract][Full Text] [Related]
29. The role of efflux transporters on the transport of highly toxic aconitine, mesaconitine, hypaconitine, and their hydrolysates, as determined in cultured Caco-2 and transfected MDCKII cells. Ye L; Yang X; Yang Z; Gao S; Yin T; Liu W; Wang F; Hu M; Liu Z Toxicol Lett; 2013 Feb; 216(2-3):86-99. PubMed ID: 23200901 [TBL] [Abstract][Full Text] [Related]
30. Molecular expression and functional evidence of a drug efflux pump (BCRP) in human corneal epithelial cells. Karla PK; Earla R; Boddu SH; Johnston TP; Pal D; Mitra A Curr Eye Res; 2009 Jan; 34(1):1-9. PubMed ID: 19172464 [TBL] [Abstract][Full Text] [Related]
31. Characterization of efflux transporters involved in distribution and disposition of apixaban. Zhang D; He K; Herbst JJ; Kolb J; Shou W; Wang L; Balimane PV; Han YH; Gan J; Frost CE; Humphreys WG Drug Metab Dispos; 2013 Apr; 41(4):827-35. PubMed ID: 23382458 [TBL] [Abstract][Full Text] [Related]
32. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2. Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821 [TBL] [Abstract][Full Text] [Related]
33. HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2). Köhler SC; Wiese M J Med Chem; 2015 May; 58(9):3910-21. PubMed ID: 25855895 [TBL] [Abstract][Full Text] [Related]
34. Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar. Kühnle M; Egger M; Müller C; Mahringer A; Bernhardt G; Fricker G; König B; Buschauer A J Med Chem; 2009 Feb; 52(4):1190-7. PubMed ID: 19170519 [TBL] [Abstract][Full Text] [Related]
35. Inhibitory potential of tuberculosis drugs on ATP-binding cassette drug transporters. Te Brake LH; Russel FG; van den Heuvel JJ; de Knegt GJ; de Steenwinkel JE; Burger DM; Aarnoutse RE; Koenderink JB Tuberculosis (Edinb); 2016 Jan; 96():150-7. PubMed ID: 26682943 [TBL] [Abstract][Full Text] [Related]
36. Expression and functional activity of breast cancer resistance protein (BCRP, ABCG2) transporter in the human choriocarcinoma cell line BeWo. Ceckova M; Libra A; Pavek P; Nachtigal P; Brabec M; Fuchs R; Staud F Clin Exp Pharmacol Physiol; 2006; 33(1-2):58-65. PubMed ID: 16445700 [TBL] [Abstract][Full Text] [Related]
37. Interactions of cyclosporin a with breast cancer resistance protein. Xia CQ; Liu N; Miwa GT; Gan LS Drug Metab Dispos; 2007 Apr; 35(4):576-82. PubMed ID: 17220244 [TBL] [Abstract][Full Text] [Related]
38. Evaluation of dual P-gp-BCRP inhibitors as nanoparticle formulation. Singh MS; Juvale K; Wiese M; Lamprecht A Eur J Pharm Sci; 2015 Sep; 77():1-8. PubMed ID: 25976226 [TBL] [Abstract][Full Text] [Related]
39. Discovery of alkoxyl biphenyl derivatives bearing dibenzo[c,e]azepine scaffold as potential dual inhibitors of P-glycoprotein and breast cancer resistance protein. Gu X; Tang X; Zhao Q; Peng H; Peng S; Zhang Y Bioorg Med Chem Lett; 2014 Aug; 24(15):3419-21. PubMed ID: 24928398 [TBL] [Abstract][Full Text] [Related]
40. Inhibition of the Human ABC Efflux Transporters P-gp and BCRP by the BDE-47 Hydroxylated Metabolite 6-OH-BDE-47: Considerations for Human Exposure. Marchitti SA; Mazur CS; Dillingham CM; Rawat S; Sharma A; Zastre J; Kenneke JF Toxicol Sci; 2017 Jan; 155(1):270-282. PubMed ID: 28031414 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]